Kestra Medical Technologies Ltd. (KMTS)
NASDAQ:KMTS
Want to see KMTS full AI Analyst Report?
KMTS Stock Chart & Stats
$19.02
--
Market closed
$19.02
--
Day’s Range― - ―
52-Week Range$13.25 - $30.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)310.69K
Market Cap
$1.26B
Enterprise Value$969.16M
Total Cash (Recent Filing)$291.32M
Total Debt (Recent Filing)$4.29M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Jul 21, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.96
Shares Outstanding58,373,352
10 Day Avg. Volume502,173
30 Day Avg. Volume310,694
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)-5.17
Price to Sales (P/S)38.89
P/FCF Ratio-12.76
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue11.58
Enterprise Value/Gross Profit23.75
Enterprise Value/Ebitda-7.57
Forecast
1Y Price Target
$27.00Price Target Upside41.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.2
Revenue Forecast (FY)$132.90M
Bulls Say, Bears Say
Bulls Say
Gross Margin And Unit EconomicsSteadily widening gross margins and attractive rental-unit economics point to improving per-patient profitability and better cash-generation potential.
Partnerships And Commercial ExpansionApproval as a managed Medicaid provider in Florida, inclusion on the VA federal supply schedule, an expanded salesforce, and a partnership with Biobeat Technologies broaden access and improve prescription conversion opportunities.
Prescription Growth And Market ShareStrong prescription volume growth driven by market share gains and an expanding prescriber base supports sustained revenue momentum and broader clinical adoption.
Bears Say
Guideline Timing UncertaintyUncertain timing for potential guideline updates creates execution risk, making the expected market acceleration and prescription increases dependent on unpredictable external decisions.
Profitability RiskNegative adjusted EBITDA indicates the business has not reached profitability, creating funding and sustainability risks if revenue growth does not continue.
Kestra Medical Technologies Ltd. News
KMTS FAQ
What was Kestra Medical Technologies Ltd.’s price range in the past 12 months?
Kestra Medical Technologies Ltd. lowest stock price was $13.25 and its highest was $30.00 in the past 12 months.
What is Kestra Medical Technologies Ltd.’s market cap?
Kestra Medical Technologies Ltd.’s market cap is $1.26B.
When is Kestra Medical Technologies Ltd.’s upcoming earnings report date?
Kestra Medical Technologies Ltd.’s upcoming earnings report date is Jul 21, 2026 which is in 74 days.
How were Kestra Medical Technologies Ltd.’s earnings last quarter?
Kestra Medical Technologies Ltd. released its earnings results on Apr 20, 2026. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.596 by -$0.014.
Is Kestra Medical Technologies Ltd. overvalued?
According to Wall Street analysts Kestra Medical Technologies Ltd.’s price is currently Undervalued.
Does Kestra Medical Technologies Ltd. pay dividends?
Kestra Medical Technologies Ltd. does not currently pay dividends.
What is Kestra Medical Technologies Ltd.’s EPS estimate?
Kestra Medical Technologies Ltd.’s EPS estimate is -0.59.
How many shares outstanding does Kestra Medical Technologies Ltd. have?
Kestra Medical Technologies Ltd. has 58,373,352 shares outstanding.
What happened to Kestra Medical Technologies Ltd.’s price movement after its last earnings report?
Kestra Medical Technologies Ltd. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.596. Following the earnings report the stock price went down -0.493%.
Which hedge fund is a major shareholder of Kestra Medical Technologies Ltd.?
Currently, no hedge funds are holding shares in KMTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kestra Medical Technologies Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.00 (41.96% Upside)
$27.00 (41.96% Upside)
Blogger Sentiment
Bullish
KMTS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 475.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $199.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-68.83%
Trailing 12-Months
Asset Growth
251.26%
Trailing 12-Months
Company Description
Kestra Medical Technologies Ltd.
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
KMTS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong operational and commercial momentum: double-digit prescription growth, 63% revenue growth, meaningful gross margin expansion, positive clinical and regulatory developments (ACE PAS and FDA algorithm approval), material market-access wins, and a healthy cash runway. These positives are balanced by near-term trade-offs: rising operating losses and adjusted EBITDA loss from investments in territory expansion and RCM, quarterly cash burn and CapEx needs to support growth, and execution/competitive risks inherent in a rapid commercial scale-up. Overall, management communicated clear progress toward scaled, durable growth while acknowledging expected near-term investment-related losses.View all KMTS earnings summariesKMTS Stock 12 Month Forecast
Average Price Target
$27.00
▲(41.96% Upside)
Technical Analysis
AngioDynamics
―
Orasure Technologies
―
Staar Surgical
―
BioLife Solutions
―
Pulse Biosciences
―
Ownership Overview
47.47% Insiders
23.21% Mutual Funds
0.25% Other Institutional Investors
23.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---